Stock Ratings / Health Care / SCLX / insiders

JSPR (41) PLUR (39) DYAI (33) BCDA (49) ⌘ Pro Terminal →

Scilex Holding Company (SCLX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Scilex Holding Company (NASDAQ: SCLX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $2.06 (-1.43% 1D, market cap $17.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #327 in composite RQD confidence.

Q: How does SCLX compare to JSPR and PLUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, JSPR (Jasper Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $17.7M) and PLUR (Pluri Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for SCLX?

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is SCLX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCLX last traded at $2.06 (-1.43% on volume of 7,406 shares), positioning the stock -50.60% below its 50-day simple moving average ($4.17) and -61.21% below its 200-day simple moving average ($5.31). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 1.5% percentile with a 14-day RSI of 14.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).

Q: Are SCLX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SCLX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

$2.06 -1.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.05

Scilex Holding Company (SCLX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $17.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.05 (-0.45%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 12.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCLX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY SCLX SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 14 (OVERSOLD (<32))

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 12.2% FCF Margin ($3.7M FCF) & 415.8% Gross Margin

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk8/20 pts (-12 pt drag)

Balance-sheet & 10-K footnote risk deducts 12 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$2.92-3.1% Next Q

Q2 (-2Q)

Grade C$2.83-17% Next Q

Q3 (-1Q)

Grade C$2.35-12.3% Next Q

Current

Grade D+$2.06-1.1% Hist 90D α

Trajectory: C (60) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCLX currently carries a cautious 52/100 (D+) rating due to SEC 10-K Forensic Risk (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.17) and Max Pain ($2.16) forces dealer call-delta covering toward $17.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SCLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SCLX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SCLX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SCLX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCLX)

✓Walkthrough of SCLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SCLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.55%▼ SUPPORT BREAKDOWN

2026-10-30O $2.05H $2.06L $1.83C $2.06VOL 49.6K

RES: $6.85SUP: $3.26SMA50: $4.17SMA200: $5.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCLX Butterfly Map → + Track SCLX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SCLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCLX)

Health Care Rank #327 of 1016 ⚔️ JSPR vs SCLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCLX vs. JSPR, PLUR, DYAI, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #327 by composite RQD confidence (52/100, grade D+) and #842 by equity capitalization ($17.5M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SCLX ACTIVE Scilex Holding Company	D+	52/100	—	96.0%	-35.0%	-1.43%	$17.5M	Benchmark Subject
JSPR Jasper Therapeutics Inc.	D-	41/100	—	—	-35.0%	-1.26%	$17.7M	/jspr-vs-sclx →
PLUR Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	/plur-vs-sclx →
DYAI Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	/dyai-vs-sclx →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-sclx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001820190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.3M	-$374.1M	$3.8M	$3.7M	$365.0M	—
FY2024 (FY)	2024-12-31	$56.6M	-$72.8M	$19.3M	$19.3M	$93.0M	—
FY2023 (FY)	2023-12-31	$46.7M	-$114.3M	-$20.7M	-$20.7M	—	—

3. SCLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Scilex Holding Company (NASDAQ: SCLX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $2.06 (-1.43% 1D, market cap $17.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #327 in composite RQD confidence.

How does SCLX compare to JSPR and PLUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, JSPR (Jasper Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $17.7M) and PLUR (Pluri Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCLX?

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCLX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCLX last traded at $2.06 (-1.43% on volume of 7,406 shares), positioning the stock -50.60% below its 50-day simple moving average ($4.17) and -61.21% below its 200-day simple moving average ($5.31). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 1.5% percentile with a 14-day RSI of 14.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).

SCLX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SCLX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SCLX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: SCLX RQD Cockpit SCLX 12M Forecast SCLX Earnings & Move SCLX Dividends & DRIP SCLX Insiders & 13F SCLX Whale Options SCLX Profit Sankey SCLX News & Why